AEON Biopharma, Inc.

AEON Biopharma, Inc. (ticker: AEON) is a clinical-stage biopharmaceutical company that completed its de-SPAC merger with Priveterra Acquisition Corp., a healthcare-focused blank-check vehicle sponsored by Priveterra Holdings LLC that conducted its initial public offering in 2021. The company is developing proprietary botulinum toxin-based drug candidates for therapeutic indications. AEON submitted an 8-K filing with the SEC on May 14, 2026, reflecting its ongoing public-company reporting obligations as a post-merger entity. Investors and analysts seeking full filing history, sponsor backgrounds, and deal-level analytics on AEON and hundreds of other SPAC transactions can sign up for complete data access at SpacDesk.